Haemonetics Balance Sheet Health
Financial Health criteria checks 3/6
Haemonetics has a total shareholder equity of $943.3M and total debt of $871.1M, which brings its debt-to-equity ratio to 92.3%. Its total assets and total liabilities are $2.2B and $1.3B respectively. Haemonetics's EBIT is $199.7M making its interest coverage ratio 22.6. It has cash and short-term investments of $195.1M.
Key information
92.3%
Debt to equity ratio
US$871.06m
Debt
| Interest coverage ratio | 22.6x |
| Cash | US$195.12m |
| Equity | US$943.32m |
| Total liabilities | US$1.26b |
| Total assets | US$2.20b |
Recent financial health updates
Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly
Jul 03Recent updates
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Haemonetics Q2 2023 Earnings Preview
Nov 04Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy
Sep 06Haemonetics reaches new 52-week high; shares up 41% YTD
Aug 24Haemonetics reports Q2 earnings beat; raises FY22 guidance
Aug 10A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
Aug 10Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly
Jul 03Haemonetics: Upside Case Hinges On Blood Plasma Collection Market
Jun 11Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
May 11Is Haemonetics (NYSE:HAE) Using Too Much Debt?
Apr 01Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
Jan 28Is Haemonetics (NYSE:HAE) Using Too Much Debt?
Dec 20Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?
Oct 28Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price
Oct 09We Think Haemonetics (NYSE:HAE) Is Taking Some Risk With Its Debt
Sep 07Financial Position Analysis
Short Term Liabilities: HAE's short term assets ($765.0M) exceed its short term liabilities ($261.8M).
Long Term Liabilities: HAE's short term assets ($765.0M) do not cover its long term liabilities ($995.4M).
Debt to Equity History and Analysis
Debt Level: HAE's net debt to equity ratio (71.7%) is considered high.
Reducing Debt: HAE's debt to equity ratio has increased from 53.9% to 92.3% over the past 5 years.
Debt Coverage: HAE's debt is well covered by operating cash flow (22.6%).
Interest Coverage: HAE's interest payments on its debt are well covered by EBIT (22.6x coverage).